期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非霍奇金淋巴瘤患儿血清IL-10、外周血淋巴细胞MHC-Ⅰ类分子的表达变化 被引量：1

下载PDF
导出
摘要 目的非霍奇金淋巴瘤患儿血清IL-10和外周血淋巴细胞主要组织相容性复合体Ⅰ(MHCⅠ)类分子的表达变化,并探讨其意义。方法选择非霍奇金淋巴瘤患儿53例为病例组,正常健康儿童20例为对照组。ELISA方法测定血清IL-10,流式细胞仪检测外周血淋巴细胞MHCⅠ表达类分子荧光强度。结果病例组血清IL-10水平为(62±3.4)pg/mL,高于对照组的(3.32±0.65)pg/mL;病例组、对照组外周血淋巴细胞MHCⅠ类分子平均荧光强度分别为(152±23)、(318±36),P<0.01。结论非霍奇金淋巴瘤患儿血清IL-10升高、外周血淋巴细胞MHCⅠ类分子表达降低。通过检测二者表达水平有助于非霍奇金淋巴瘤的早期诊断。
作者 于敏 刘丁 孙雪晶 任新燕 玄春花
机构地区 聊城市东昌府区妇幼保健院
出处 《山东医药》 CAS 2013年第34期85-86,共2页 Shandong Medical Journal
关键词 淋巴瘤 非霍奇金 白细胞介素-10 淋巴细胞 主要组织相容性抗原Ⅰ
分类号 R725.5 [医药卫生—儿科]
  • 相关文献

参考文献10

  • 1Guney N, Soydinc HO, Basaran M, et al. Serum levels of interleu- kin-6 and interleukin-10 in Turkish patients with aggressive non- Hodgking lymphoma[J]. Asian Pac J Cancer Prev, 2009,10 (4) : 669-674.
  • 2Mocellin S, Panelli MC, Wang E, et al. The dual role of IL-10 [J]. Trends Immunol, 2003,24( 1 ) :36-43.
  • 3贺建霞,赵志强,王艳峰,杨斌,苏文.非霍奇金淋巴瘤患者外周血T细胞亚群及NK细胞检测的临床意义[J].白血病．淋巴瘤,2013,22(7):436-438. 被引量：15
  • 4Leffers N, Lambeck A J, de Graeff P, et al. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation[J]. Gynecol Oncol, 2008, 110(3) :365-373.
  • 5Martini M, Testi MG, Pasetto M, et al. IFN-gamma-mediated up- modulation of MHC class I expression activates tumor-specific im- mune response in a mouse model of prostate cancer[ J]. Vaccine, 2010,28(20) :3548-3557.
  • 6Maruyama T, Mimura K, Sato E, et al. Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinom[J] Br J Cancer, 2010,103 (4) :552-559.
  • 7Jordanova ES, Gorter A, Ayachi O, et al. Human leukocyte anti- gen class I, MHC class I chain-related molecule A, and CDs+/reg- ulatory T-cell ratio: which variable determines survival of cervical cancer patients[J]. Clin Cancer Res, 2008,14(7) :2028-2035.
  • 8Bijen CB, Bantema-Joppe EJ, de Jong RA, et al. The prognostic role of classical and nonclassical MHC class I expression in endom- etrial cancer[ J]. Int J Cancer, 2010,126(6) : 1417-1427.
  • 9Simpson JA, A1-Attar A, Watson NF, et al. Intratumoral T cell in- filtration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer[J]. Gut. 2010,59(7) :926-933.
  • 10涂三芳,李玉华.复发难治B细胞性非霍奇金淋巴瘤的治疗进展[J].山东医药,2012,52(9):95-98. 被引量：11

二级参考文献24

  • 1赵成艳,马荣,王忠利,马恩龙,王丽红.非霍奇金淋巴瘤患者T细胞亚群、NK细胞检测的临床意义[J].中国免疫学杂志,2006,22(2):180-181. 被引量：26
  • 2蒋红飞.癌症患者的T淋巴细胞亚群免疫功能的研究[J].国际检验医学杂志,2006,27(7):660-661. 被引量：22
  • 3Coiffier B.Rituximab in combination with CHOP improves survivalin elderly patients with aggressive non-Hodgkin’s lymphoma[J].Semin Oncol,2002,29(2 Suppl 6):18-22.
  • 4Shivakumar L,Armitage JO.Bcl-2 gene expression as a predictor ofoutcome in diffuse large B-cell lymphoma[J].Clin Lymphoma Mye-loma,2006,6(6):455-457.
  • 5Kewalramani T,Zelenetz AD,Nimer SD,et al.Rituximab and ICEas second-line therapy before autologous stem cell transplantation forrelapsed or primary refractory diffuse large B-cell lymphoma[J].Blood,2004,103(10):3684-3688.
  • 6El Gnaoui T,Dupuis J,Belhadj K,et al.Rituximab,gemcitabineand oxaliplatin:an effective salvage regimen for patients with re-lapsed or refractory B-cell lymphoma not candidates for high-dosetherapy[J].Ann Oncol,2007,18(8):1363-1368.
  • 7Emmanouilides C,Lill M,Telatar M,et al.Mitoxantrone/ifos-famide/etoposide salvage regimen with rituximab for in vivo purgingin patients with relapsed lymphoma[J].Clin Lymphoma,2002,3(2):111-116.
  • 8Appelbaum FR.Hematopoietic cell transplantation for non-Hodgkin’slymphoma:yesterday,today,and tomorrow[J].J Clin Oncol,2008,26(18):2927-2929.
  • 9Peniket AJ,Ruiz de Elvira MC,Taghipour G,et al.An EBMT reg-istry matched study of allogeneic stem cell transplants for lymphoma:allogeneic transplantation is associated with a lower relapse rate but ahigher procedure-related mortality rate than autologous transplanta-tion[J].Bone Marrow Transplant,2003,31(8):667-678.
  • 10Goy A,Bernstein SH,Kahl BS,et al.Bortezomib in patients withrelapsed or refractory mantle cell lymphoma:updated time-to-eventanalyses of the multicenter phase 2 PINNACLE study[J].Ann On-col,2009,20(3):520-525.

共引文献24

同被引文献13

  • 1高小青,谢艳华.胃癌患者血清IL-6、IL-8及IL-10的表达及意义[J].山东医药,2008,48(5):75-76. 被引量：9
  • 2Ohsawa M, Ikura Y, Fukushima H, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma [ J ]. Oncology, 2005, 68: 422-431.
  • 3Strauss L,Bergmann C ,Szezepanski M ,et al. A unique subset of CD4+ CD25 high Foxp3+ T ceils secreting interleukin-10 and transforming growth factor-betal mediates suppression in the tumor mieroenvironment [ J ]. Clin Cancer Res, 2007, 13:4345- 4354.
  • 4Mocellin S,Panelli MC, Wang E, et al. The dual role of IL-10 [ J]. Trends Immunol, 2003,24:36-43.
  • 5Zeng L, O'Connor C,Zhang J, et al. IL-IO promotes resistance to apoptosis and metastatic potential in lung tumor cell lines [ J ]. Cytokine, 2010, 49:294-302.
  • 6Candido EB, Silva LM, Carvalho AT, et al. Immune response e- valuation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer [ J ]. Reprod Sci. 2013. 20:828-837.
  • 7Guney N,Soydinc HO,Basaran M,et al. Serum levels of inter- leukin-6 and interleukin-10 in turkish patients with aggressive non-Hodgkin' s lymphoma [ J ]. Asian Pac J Cancer Prey, 2009, 10:669-674.
  • 8Nacinovi-Duleti A, Stifter S, Dvomik S, et al. Correlation of ser- um IL-6 ,IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma [J]. Int J Lab Hematol, 2008, 30:230-239.
  • 9Leeh-Maranda E, Bienvenu J, Broussais-Guillaumot F, et al. Plasma TNF-alpha and IL-10 level-based prognostic model pre- dicts out-come of patients with diffuse large B-ceU lymphoma in different risk groups defined hy the international prognostic in- dex[J]. Arch lmmunol Fher Exp (Warsz), 2010, 58: 131-141.
  • 10刘杰,田志刚,冯进波,魏海明.人肿瘤细胞中Th2类细胞因子的强势表达[J].中华肿瘤杂志,1998,20(2):105-107. 被引量：50

引证文献1

二级引证文献2

山东医药
2013年 第34期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部